ReviewPLoS pathogens2019
Macrophage nuclear receptors: Emerging key players in infectious diseases.
Review in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Regional signaling controls stem cell-mediated regeneration in an invertebrate chordate.PLoS biology · 2026Article
- Pulmonary inflammation in severe pneumonia is characterised by compartmentalised and mechanistically distinct sub-phenotypes.Nature communications · 2026Article
- PPAR-γ, RXR-α, and VDR Expression in Gingival Tissues of Patients with Grade B and Grade C Periodontitis: A Cross-Sectional Clinical Immunohistochemistry Study.Journal of clinical medicine · 2026Article
- NR4A nuclear receptor expression in human macrophages mediates apoptosis and controls Mycobacterium tuberculosis growth.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Loss of NR2F6 Protects from Salmonella Typhimurium Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions.Signal transduction and targeted therapy · 2025Review
- Regulation of NK cell development, maturation, and antitumor responses by the nuclear receptor NR2F6.Cell death & disease · 2025Article
- Transcription factors in the development and treatment of immune disorders.Transcription · 2025Review
- Activation of nuclear receptors correlates with tuberculosis severity and is a target for host-directed therapy.Frontiers in cellular and infection microbiology · 2025Article
- Immune-endocrine crossroads: the impact of nuclear receptors in Tuberculosis and Chagas disease.Frontiers in endocrinology · 2025Review
- Tolerance to Haemophilus influenzae infection in human epithelial cells: Insights from a primary cell-based model.PLoS pathogens · 2024Article
- Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression.JCI insight · 2024Article
- Human nuclear hormone receptor activity contributes to malaria parasite liver stage development.Cell chemical biology · 2023Article
- Redox regulation of the immune response.Cellular & molecular immunology · 2022Review
- Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease.Communications biology · 2022Article
- Differential expression of nuclear hormone receptors by dendritic cell subsets in human vaginal mucosa and skin.Frontiers in immunology · 2022Article
- The Impact of Aging on the Lung Alveolar Environment, Predetermining Susceptibility to Respiratory Infections.Frontiers in aging · 2022Review
- Role of Bile Acids and Nuclear Receptors in Acupuncture in Improving Crohn's Disease.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Monocyte and Macrophage Lipid Accumulation Results in Down-Regulated Type-I Interferon Responses.Frontiers in cardiovascular medicine · 2022Article
- Early Transcriptional Liver Signatures in Experimental Visceral Leishmaniasis.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear receptors (NRs) are ligand-activated transcription factors that are expressed in a variety of cells, including macrophages. For decades, NRs have been therapeutic targets because their activity can be pharmacologically modulated by specific ligands and small molecule inhibitors. NRs regulate a variety of processes, including those intersecting metabolic and immune functions, and have been studied in regard to various autoimmune diseases. However, the complex roles of NRs in host response to infection are only recently being investigated. The NRs peroxisome proliferator-activated receptor γ (PPARγ) and liver X receptors (LXRs) have been most studied in the context of infectious diseases; however, recent work has also linked xenobiotic pregnane X receptors (PXRs), vitamin D receptor (VDR), REV-ERBα, the nuclear receptor 4A (NR4A) family, farnesoid X receptors (FXRs), and estrogen-related receptors (ERRs) to macrophage responses to pathogens. Pharmacological inhibition or antagonism of certain NRs can greatly influence overall disease outcome, and NRs that are protective against some diseases can lead to susceptibility to others. Targeting NRs as a novel host-directed treatment approach to infectious diseases appears to be a viable option, considering that these transcription factors play a pivotal role in macrophage lipid metabolism, cholesterol efflux, inflammatory responses, apoptosis, and production of antimicrobial byproducts. In the current review, we discuss recent findings concerning the role of NRs in infectious diseases with an emphasis on PPARγ and LXR, the two most studied. We also highlight newer work on the activity of emerging NRs during infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.